Summary. The effects of a microfilament-modifier (cytochalasin B), of mitotic spindle-inhibitors (colchicine and vinblastine) and of a microtubule-stabilizer (I)20) on glucagon secretion were studied in vitro, using pieces of pancreas from duct-ligated rats. Cytochalasin B (10 ~g/ ml) potentiated arginine-induced glucagon release, but was without effect on unstimulated glucagon release. Colchioine (10-aM) and vinblastine (10-4M) similarly stimulated arginine-induced glucacon release; colehicine did not affect unstimulated glucagon release. Deuterium oxide (!00%, v/v) reversibly inhibited arginine-induced glucagon secretion. If it is assumed that the above mentioned drugs specificMly interact with microfilaments and microtubules in the A S cells, our results would suggest that a microtubular-microfilarnentous system indeed participates in the process of glucagon secretion. The intimate mechanism by which such a system may apparently play both a restrictive and effector role in glucagon release remains, however, to be elucidated.
A number of ultrastructural studies have demonstrated, like in a variety of specialized contractile cell types [i, 48] , the presence of microtubular and microfilamentous structures ~dthin the hya]oplasm of several endocrine secretory cells. Such structures have, in particular, been recognized in the pancreatic B [2, 19, 29, 31, 38, 39] and A 2 cells [11, 14] , the follicular [35, 37, 49] and the caleitonin-releasing C cells [4] of the thyroid gland and the somatotroph of the anterior pituitary gland [15] . Accordingly, it has been suggested that, in these endocrine cells, microtubules and microfilaments might control the intracytoplasmic migration and exocytosis of secretory granules. This is supported by functional investigations, which have demonstrated that agents known to affect the structure or function of microfilaments and microtubules (e.g. cytochalasin B, colchicine, vinblastine, deuterium oxide) influence the release of several hormones. Thus, these agents were found to influence the release of insulin [7, 8, 19, 20, 21, 29--32, 38, 43, 46, 47, 51] , of thyroid hormones [35, 36, 49, 50] , of cateeholamines from the adrenal medulla [9, 10, 40, 45] , of ACTI-I and growth hormone from the anterior pituitary gland [18, 41] , of posterior pituitary hormones [10] and recently, while this study was in progress, also that of glucagon from the pancreatic A 2 cell [11, 44, 51] .
The present functional studies were undertaken in order to document the possible participation of microtubules and microfilaments in the process of glucagon release which, like that of insulin and other hormones, apparently involves an emiocytotic extrusion of secretory granules into the extracellular space [13, 14, 22, 27] . The agents studied were eytochalasin B, which is thought to induce a disruption of mierofilaments without interfering with microtubules [48] ; colchicine, which induces a depolymerisatiou of microtubules through its binding to the protein subunits of these organelles [1] ; vinblastine, which causes an aggregation of the microtabular protein in crystalline-like deposits [3] ; and deuterium oxide (D~O), which stabilizes the microtubules [16] . It should be emphasized that each of these drugs was used at only one concentration, selected on the basis of its efficiency upon the B cell microtubular-microfilamentous system, as previously assessed by both ultrastructural and biochemical criteria [29, 30] . A preliminary account of this work has been presented in abstract [24] .
Materials and Methods

Incubation Procedure
The incubation procedure has been described in detail elsewhere [25] . All incubations were carried out at 37.5~ in 2 ml of bicarbonate-buffered medium (pH 7.4) containing calcium (2 mEq/1), bovine albumin (5 mg/ml; Pentex, fraction V powder, Miles-Severac, Ltd, Maidenhead, Bershire, England) and equilibrated against a mixture of 02 (95%) and CO~ (5%). All media were supplemented with glucose (8.3 raM) and "Trasylol" (833 KIU/ml; kindly supplied by Drs. N. Kiesselbach and G. Wald, Bayer-Wuppertal-Elberfeld, Western Germany, and Bayer-Pharma, Brussels, Belgium).
Pancreatic tissue was removed from female, fed albino rats (body weight: 130--160 g) in which the pancreatic duct draining the splenic portion of the pancreas had been ligated for 3 to 4 weeks, according to the technique reported previously [23] . Two rats were used in each experiment, the pancreatic tissue being cut into eight pieces, which were distributed among 8 flasks, so that each flask contained 2 small pieces (total weight: 4 to 10 rag) obtained from 2 different animals. The flasks were incubated for successive periods of 30 min each, so that each sample of pancreatic tissue served as its own control. No measurement was made during the first period of incubation. Between the various incubation periods, the pieces of pancreatic tissue were not submitted to a washing procedure. However, care was taken to remove any excess of medium carried along with the pieces of pancreatic tissue by delicate contact with a blotting paper.
Two types of experimental design were used. In the first, which we shall refer to as "simple experimental design", all the samples of pancreatic tissue were treated similarly. Two experiments of this type were performed in order to obtain 16 individual results (see Figs. 5, 9) . In the second type, referred to as "parallel experimental design", the samples of pancreatic tissue were divided into two or three groups, each group being treated differently. In such a case, four to five identical experiments were performed in order to obtain 12 to 16 individual results for each treatment" (see Figs. 2, 3, 4, 6, 7, 8) .
Drugs
Cytoehalasin B (Imperial Chemical Industries, Macelesfield, England) was dissolved in dimethylsulfoxide (DMSO, Merck, Darmstadt, Western Germany) and added to the incubation medium so as to reach a final concentration of 10 ~g/ml. The same volume of DMSO (10 ~l/ml) was also added as a control to media containing no cy~ochalasin B. It had been previously ascertained that, at this concentration, DMSO did not affect insulin release [29, 38] . Colchicine (Sigma Chemical Co., St. Louis, USA) and vinblastine sulfate ("Velbe", Eli Lilly Co., Christiaens, Brussels, Belgium) were used at a concentration of 10-~M. In the experiments using D20 (99.9% purity, Merck, Darmstadt, Western Germany) all H20 was replaced by D20.
Glucagon and Insulin Determinations
The glueagon content of the incubation media was estimated by radioimmunoassay [26] and the rate of glucagon release expressed as pg/mg wet weight pancreatic tissue/30 rain. l~lI-labelled porcine glucagon (CNTS, Paris, France) and purified crystalline beefpork glueagon (kindly donated by Dr. Mary Root, Lilly l~esearch Laboratories, Indianapolis, USA) were used as tracer and standard for these determinations. The properties of the anti-glueagon serum used in the assay have been documented elsewhere [26] . The insulin content of the incubation media was determined by the method of Wright et al. [52] and the rate of insulin release expressed as ~U/mg wet weight pancreatic tissue/30 min. Guinea.pig anti-insulin serum (a gift from Dr. P.H. Wright, University of Indiana, Indianapolis, USA) and 125I-labelled bovine insulin were used for these measurements. Purified crystalline rat insulin was used as reference (Lot R 170, a gift from Dr. J. Schlichtkrull, Novo l~esearch Institute, Copenhagen, Denmark). None of the agents used, except D~O, affected the standard curves in either the glueagon or the insulin assays. The incubation media composed of 100% D20 caused a small upward shift of the glucagon standard curve resulting in a diminished sensitivity (Fig. 1) . This shift was taken into account in the estimation of the glueagon content of these media.
Calculations and Presentation of Results
For each incubation period, the mean values (• SEM) for glucagon and insulin secretion were calculated by pooling the results obtained in separate experiments (n~-12 to 16). The effect of any stimulus was assessed individually for each of the samples of pancreatic tissue and expressed as per cent change over the preceding control period. The statistical significance of the observed changes in both glucagon and insulin secretions were analysed using Student's paired t test, according to Snedecor [42] . In some cases, the mean changes in secretion observed in distinct sets of treatments were compared by use of Student's nonpaired t test.
Results
Control Experiments
When pieces of pancreatic tissue were incubated for 10 successive periods of 30 rain each in control media (glucose 8.3 raM) a progressive decrease in the rate of both glucagon and insulin release was observed (Fig. 2) . This behaviour confirms previous findings [25] . When arginine (10 raM) was added to the medium during incubation periods 4 and 5, the expected stimulation of both glucagon and insulin release was noticed (Fig. 3) . In terms of paired relative change, the response of the A 2 cell was of smaller amplitude than that of the B cell.
Effects of Cytochalasin B a. Effect of Cytochalasin B on Arginine-Induced
Glucagon Release. The effect of cytochalasin B on arginine-induced glucagon release was studied using a "parallel experimental design" (Figs. 3 and 4) . The 8 samples of pancreatic tissue were divided into two groups, the first one being exposed, during incubation periods 4 and 5, to a 10 mM arginine stimulus alone, and the second one being exposed to 10 mM arginine and 10 ~g/ml cytochalasin B. Fig. 4 illustrates the results which were obtained in the presence of arginine and cytochalasin B. For the sake of comparison, the results of the corresponding control experiment (see Fig. 3 ) are reported on the graph by the dotted lines. During control periods 2 and 3, there was no significant difference in both gincagon and insulin outputs between the two experimen-tal groups. However, cytochalasin B clearly potentiated the response of the A S cell to arginine. Thus, the arginine-i~duced increment in glueagon release averaged-~55 • 10 (period 4) and -~40 • 10% (period 5) in the absence of cytoehalasin B, compared with -~ 147 =~ 22 (period 4) and ~-179 :~ 24% (period 5) in the presence of the mould metabolite. Using the nonpaired t test, the enhancfiag effect of cytochMasin B proved to be highly significant (P<0.001) in both periods 4 and 5. (Fig. 4) . However, the output of both hormones from the pieces of pancreas which had been exposed to cytochalasin B remained somewhat higher than that found, at the same time, in pieces never exposed to the mould metabolite. This difference in hormonal output during incubation periods 6 and 7, which suggests that the facilitating action of cytochalasin B was only partially reversible, failed to achieve statistical significance in the case of glueagon, but was highly significant (P < 0.001) in the case of insulin. Determinations for the standard curve were performed in the presence of either normal or deuteriated media (100 ~l, as in any sample determination), the final volume of the reaction mixture in veronal buffer amounting to 700 ~1 per tube. The per cent of "undamaged" 13tI-glucagon bound to the antibody was calculated from the radioactivity adsorbed on dextran-charcoal respectively in the absence (F) or presence (F') of antiserum. Also shown is the final dilution of the anti-glucagon serum (f.d.)
Cytochalasin B also facilitated arginine-induced insulin release (Fig. 4, lower panel) . The arginine-induced increment in insulin output averaged q-237zk36 (period 4) and -k 376 • 50% (period 5) in the absence of cytochalasin B and + 421 • 41 (period 4) and + 613 ~: 78% (period 5) in its presence. The enhancing effect of cytochalasin B was significant (P < 0.01 or less) in both periods 4 and 5.
When the pieces of pancreas were returned to the normal control media during periods 6 and 7, the release of both glucagon and insulin rapidly declined Fig. 2 ). Thus, a steady decline in the rate of glucagon secretion was also observed when the pieces of pancreatic tissue were transferred back to the control media during periods 6 and 7.
The release of insulin evoked by glucose (8.3 mM) was enhanced in the presence of cytochalasin B, and progressively returned to its control value after removal of the mould metabolite (Fig. 5, lower panel) .
Effects of Colchicine and Vinblastine a. Effects of Colchicine and Vinblastlne on ArginineInduced Glucagon
Release. These studies were performed using a "parallel experimental design". The 8 samples of pancreatic tissue were divided into two effect of arginine, expressed in terms of paired changes over the preceding control periods, is illustrated in Fig. 6 . Pretreatment of the pancreatic tissue with a mitotic spindle-inhibitor markedly enhanced the glucagon secretory response to arginine. Thus, prior exposure to colchicine enhanced the arginine-induced increment in glucagon release from -? 2I ~ 9 to + 120 4-25%, while prior exposure to vinblastine augmented the glucagon response to arginine from -? 30 4-12 up to -7864-13%. By non-paired comparison, these Fig. 3 . Effect of a 10 mM arginine stimulus, applied during incubation periods 4 and 5, on the release of glucagon and insulin. The results were obtained using a "parallel experimental design". They illustrate the control experiment corresponding to Fig. 4 . Therefore, DMSO (10 fzl/ml) was also present in the incubation media during periods 4 and 5. The absolute rates of secretion measured during incubation periods 2 to 7 are shown in the panel to the left, and the paired changes in hormonal output induced by arginine are shown in the panel to the right. The results represent the mean (=~ SEM) of 16 determinations. Levels of significance : * P < 0.05 ; * ** P < 0.01 ; * ** * P < 0.001 groups. Half of the samples was incubated for 120 to 150 min in the normal control media and thereafter exposed for 30 rain to arginine (10 mM). The other half of the samples was similarly incubated for 120 to 150 rain, but in the presence of either vinblastine or colehicine (10-4M) and, thereafter, also exposed to arginine (10 mM). Vinblastine and colchicine were present during the 30 min stimulatory period. The . Effect of a 10 mM arginine stimulus applied, coneomitantly with cytochalasin B (10 ~zg/ml), during incubation periods 4 and 5, on the release of glucagon and insulin. The results were obtained using a "parallel experimental design". For the sake of comparison, the control values illustrated in Fig. 3 are reported on the graph by the dotted lines. Number of determinations and levels of significance as for Fig. 3 facilitating effects proved to be significant in the case of both colchicine (P<0.001) and vinblastine (P< 0.01).
As shown in Fig. 6 (lower panel), the secretory response of the B cell to arginine was partially inhibited in pancreatic tissue pretreated with a mitotic spindleinhibitor. Colchicine reduced the a'rginine-induced increment in insulin output from -? 532 4-83 to -? 182 -4-30~o ; vinblastine reduced the increment from -? 298 -4-51 to -? 196 ~c 23%. Once again, the inhibitory effect of mitotic spindle-inhibitors proved to be significant, when tested by non-paired comparison.
b. Effects of Colchieine on Unstimulated Glucagon
Release. These experiments were performed using a "parallel experimental design". The 8 samples of pancreatic tissue were divided into three groups. The first group (3 samples) was incubated during 10 successive periods of 30 min, each in the normal control media; the results obtained in this group are shown in Fig. 2 . The second group (3 samples) was incubated in the normal control media during incubation periods 1 to 3 and exposed to colehicine (10-4M) during incubation ated (or even glucose-suppressed) glucagon release. Likewise, the addition of Colehicine for only 60 rain (periods 4 and 5) had no significant effect on the decreasing pattern of glucagon release normally observed in the present system (Fig. 8) .
Surprisingly, prolonged exposure to colchicine did not inhibit, but actually enhanced, the release of insulin at the 8.3 mM glucose concentration (Fig. 7,  lower panel) . By non-paired comparison the difference between control (Fig. 2) and experimental (Fig. 7) (Fig. 7) . The third group (2 samples) was incubated in the normal control media during incubation periods 1 to 3, exposed to colchicine during periods 4 and 5, and subsequently returned to the normal control media during incubation periods 6 to 10 (Fig. 8) . Five experiments were performed in order to obtain 15 individual results for the first and the second group, and 10 for the third. As shown in Fig. 7 , almost identical rates of glucagon release were observed during periods 4 to 10, whether in the presence or absence of colchicine, indicating that eolchicine had no influence on unstimul- Fig. 3 . The levels of probability (P) indicated on the graph refer to the influence of mitotic spindle-inhibitors, as tested by nonpaired comparison, on the arginine-indueed paired changes in hormonal output was significant (P < 0.05 or less) from the 6th period onwards. As shown in Fig. 8 (lower panel) , the enhancing effect of colchicine upon insulin release was even more marked when, after 60 rain exposure to the mitotic spindle-inhibitor, the pieces of pancreas were transferred to the control media.
~l. Effects of D20 on Arginine-Induced Glucagon Release
The effects of D~O were investigated using a "simple experimental desigrs (Fig. 9) . Arginine (10 m~) was present throughout the incubation procedure and all H20 was replaced by D~O during periods 4 to 6. D~O significantly inhibited arginine-induced glucagon reIease, although there was a progressive tendency for 5--3: --81-_t=3%; 6--3: --80~:3%). The inhibitory effect of DeO on insulin secretion, like that on glueagon release, was readily reversible (Fig. 9 , lower panel; 7--6: +365~=39%, P<0.001).
Discussion
The validity of the present model for the measurement of hormonal release by insular tissue has been Fig. 2 are reported on the graph by the dotted lines glucagon secretion to escape from such an inhibition (Fig. 9 , upper panel; 4--3 : --38 ~ 3% ; 5--3 : --22 • 4%; 6--3: --18-t-4%). A striking rebound in glucagon release was observed when the pieces of pancreatic tissue were returned to the It20-containing media during incubation period 7, indicating that the D20-induced inhibition of glucagon release was readily reversible (Fig. 9 , upper panel; 7--6: +99j=16%, P < 0.00t). D20 also markedly inhibited arginine-induced insulin release (Fig. 9 , lower panel; 4--3 : --84 q-1% ; documented in previous studies [23, 25] and is further assessed by the changes in insulin release here observed. Indeed, the reversible enhancing action of cytochalasin B upon insulin secretion evoked by either glucose (Fig. 5) or arginine (Fig. 4) is in good agreement with previous data collected in isolated islets [20, 29, 38] , monolaycr cultures of newborn rat pancreas [32, 51] and the isolated perfused rat pancreas [7, 47] . The inhibition of arginflle-indueed insulin release by colchieine or vmblastme (Fig. 6 ) and by D~O (Fig. 9 ) also extends previous findings collected in other iv vitro systems [19, 21, 30--32, 43] . Even the facilitation by colchicine of insulin release at 8.3 mM glucose concentration (Figs. 7 and 8) is consistent with the recent finding that mitotic spindle-inhibitors both facilitate and inhibit insulin release [8, 46] , the facilitation being masked only under those conditions associated with both a sustained and marked stimulation of insulin release (e.g. at a 16.7 mE glucose concentration) and an extended disruption of the microtubnlar apparatus (e.g. as a result of prolonged exposure to eolchicine). Fig. 9 . Effect of D20, introduced in the media during incubation periods 4 to 6, on arginine-induced glucagon and insulin release. Glucose (8.3 raM) and arginine (10 raM) were present throughout the incubation procedure. The results were obtained using a "simple experimental design" and represent the mean (~= SEM) of 16 determinations. Levels of significance as for Fig. 3 We have emphasized elsewhere [28] our reasons for believing that the iniinence upon insulin release of cytochalasin B, eolehicine and D~O is due to fnnctional alteration of the mierotubular-microfilamentous apparatus rather than a non-specific interference with the recognition of secretagognes and subsequent changes in the handling of cations by the B cell.
Effect of Cytochalasin B upon Glucagon Release
Cytochalasin B reversibly enhanced arginine-induccd glucagon secretion (Fig. 4) , but failed to affect the unstimulated (or inhibited) release of glucagon at 8.3 mE glucose concentration (Fig. 5) , suggesting that the mould metabolite facilitates, but does not initiate, the secretory process in the A S cells. In monolayer cultures of newborn rat pancreas, however, cytochalasin B was found to augment glucagon release at both high and low glucose levels [51] .
In our view, the failure of cytochalasin B to enhance glucagon release at 8.3 mM glucose concentration suggests that the effect of the mould metabolite upon the A S cell secretory activity cannot be solely caused by inhibition of glucose transport, as reported in a variety of other cells [6, 12, 17, 33, 53] . It is also unlikely that the changes in glueagon release are the consequence of concomitant changes in insulin release. The facilitation of arginine-induced insulin secretion by cytoehalasin B would cause, if anything, inhibition rather than augmentation of glucagon release [34] . Although other explanations are conceivable [5] , we suggest that the effect of cytochalasin B upon glucagon release is mainly due to its well documented effect on microfilamentous structures. It is thus conceivable, as postulated for insulin release from the B cell [38] , that the microfilamentous system of the A 2 cell participates in the controlled access of glucagon secretory granules to the cell membrane, a process somehow facilitated in the presence of cytochalasin B. However, the confirmation of such an hypothesis awaits further biochemical and ultrastructural studies in the A S cell. It also remains to be elucidated why cytochalasin B augments insulin and glucagon secretion, but inhibits the release of thyroid hormones [35, 50] , catecholamines [10], growth hormone [41] and neurohypophyseal hormones [10] in appropriately stimulated endocrine glands. The contrast between facilitated glucagon (or insulin) release and inhibited growth hormone secretion is especially intriguing, because both effects were observed with the same concentrations of cytochalasin B (1 to 10 ~g/ml) and because hormonal release in both systems is thought to occur through an emiocytotic process [13, 14, 15, 22, 27] .
Effects of Colehicine and Vinblastine upon Glucagon Re.
lease After a prolonged exposure to either colchicine or vinblastine; the glucagon secretory response to arginine was enhanced (Fig. 6) , while no significant effect of colchicine upon unstimulated glucagon release could be detected (Figs. 7 and 8) . The facilitation of arginineinduced glucagon release is in good agreement with the findings of Edwards and Howell in isolated guinea-pig islets of Langerhaas [11] , but at variance with a preliminary note [44] suggesting that the arginine-induced release of glucagon by the isolated perfused rat pancreas is decreased after 45 to 60 rain prcperfusion with either colchicine (10~M) or vincristine (10-4M). The present failure of colchieine to affect unstimulated glucagon release is also at variance with the findings of Edwards and Howell, who reported that colchicine or vinblastine enhanced unstimulated (5.5 mM glucose) and inhibited (5.5 mlVi glucose -F 5 mM octanoic acid) glucagon secretion. The explanation for such discrepancies remains to be found. In our view, the most pertinent finding is the facilitation of arginineinduced glucagon release by mitotic spindle-inhibitors at a time when arginine-induced insulin release is concomitantly reduced. Once again, we do not believe that the enhanced release of glucagon is the consequence of the reduction in insulin output, since we have previously shown that insulin deficiency, as caused by large amounts of anti-insulin serum, fails to potentiate arginine-induced glucagon release in the present system [25] . As recently observed in the adrenal medulla [9, 10, 45] , the colchicine-or vinblastine-induced changes in hormonal release could be due to pharmacological properties of these drugs, unrelated to their effect on the microtubular apparatus. Nevertheless, it is unlikely, from both pre~ous [11] and the present experiments, that a metabolic rather than biophysical mechanism is responsible for the effects of mitotic spindle-inhibitors on insulin and gluCagon secretion. Indeed, whereas the secretory response of the A2-and B cell, respectively, to a given metabolic condition (e.g. inhibition of glucose metabolism) are usually inversely related, we purposely used arginine, which, in contrast to most other metabolic substrates, stimulates both insulin and glucagon release. Any alteration in the process of arginine recognition by the pancreatic endocrine cells would be expected, therefore, to affect concomitantly and in the same direction both arginine-induced insulin and glucagon release, which was not the case in our experiments. If one assumes that the present changes in insulin and glncagon secretion are indeed mediated through a disruption of microtubules, our results would suggest that the microtubular apparatus, which in the B cell is thought to control the oriented intracellular translocation of secretory granules, normally restrains the access of glucagon secretory granules to sites of exocytosis in the A 2 cells.
Effect of DeO upon GIucagon Release
DeO partially, and reversibly, inhibited argininestimulated glucagon release, with a possible trend for glucagon secretion to progressively and partially escape from the D20-induced inhibition (Fig. 9) . As already described for insulin secretion [30, 31] , a rebound in glucagon release was observed at the time of removal of the pancreatic pieces from the deuterfated media.
Because De0 is thought to impair microtubular function in endocrine [30, 31, 35, 36] as well as non endocrine cells [16] , the inhibitory effect of I)20 upon glucagon release may appear at variance with the results obtained with mitotic spindle-inhibitors, suggesting a restrictive role for the microtubular apparatus in glucagon release. However, such an apparent inconsistency might well be due to the fact that the stabilizing action of D20 upon the microtubularmicrofilamentous system results in an impairment of both the intracellular translocation of secretory granules along the microtubnlar pathways and exocytosis of those granules already located in close vicinity to the cell web [43] .
Once again, confirmation of such an hypothesis is dependent on more knowledge of the biochemical, ultrastruetural and functional properties of microtubules in the A 2 cell. Meanwhile, the results of the present study are compatible with the idea that, as in a variety of other endocrine cells, a microtubularmicrofilamentous system is intimately involved in the process of glucagon release by the pancreatic A 2 cell. It is most intriguing, in this context, that calcium deprivatiov, which is claimed to arrest insulin release by inactivating the B cell microtubular-microfilamentons system [28] , was recently found to enhance glucagon release by the A s cell [25] .
